| ▲ | yowlingcat 2 days ago | |
This is not a great "study" if you can call it that. Let me be specific by pointing a passage that's doing a lot of the heavy lifting: ``` After controlling HDL and LDL cholesterol, uncontrolled high blood pressure, atherosclerotic cardiovascular disease, cocaine use, alcohol use and several other lifestyle risk factors, the researchers found that new cases of diabetes were significantly higher in the cannabis group (1,937; 2.2%) compared to the healthy group (518; 0.6%), with statistical analysis showing cannabis users at nearly four times the risk of developing diabetes compared to non-users. ``` Note "nearly four times the risk of developing diabetes" -- this feels like a dangerous exaggeration of "four times the correlation of having developed diabetes." No controls for diet, exercise, etc. In comparison to a gold standard clinical trial this is about as far as you can go on the other end. That's not to say that I think that a prospective link doesn't merit deeper research -- far from it. In fact, Novo Nordisk has an anti-obesity drug in phase 2a trials, monlunabant [1], that serves as a CB1 (cannabinoid receptor 1) inverse agonist which has a mechanism of action inverse to THC. The clinical trials are showing that it creates modest weight loss, so it seems that there's likely something to how that receptor is activated that could cause weight gain. What's not clear to me is whether all the other receptors that THC activates create a compound effect at a population health level that leads to net weight gain and the development of diabetes, the inverse, or non-correlated outcomes, and whether those occur across the board or differentially based on genetic makeup. | ||